In Alzheimer’s disease models, berberine has shown promise by reducing both intracellular and extracellular Aβ levels, modulating key proteins involved in amyloid metabolism, such as amyloid precursor protein (APP) and β-secretase 1. This evidence concerns the gene APP and early-onset autosomal dominant Alzheimer disease.